Our Mission
SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our unique platform
Nevisense
The unique Nevisense platform utilizes advanced EIS- technology combined with AI to empower healthcare professionals by improving diagnostic accuracy, enabling disease monitoring, and facilitating early detection of skin cancer. The Nevisense procedure is non-invasive and provides clinicians with objective and actionable data, at point-of-care. It has been developed based on 20+ years of research from the Karolinska Institute and several years of clinical experience.
Read more
News
Events
SciBase Partners with Skinobs to Offer Nevisense on Global Cosmetic Testing Platform
February 28, 2024STOCKHOLM, SWEDEN, - February 28, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Skinobs, a leading global platform connecting researchers with the tools they need for their cosmetic and medical research. Through this partnership, SciBase will now offer Nevisense for assessing skin barrier function within cosmetic testing on the Skinobs platform.
Keynote speakers presented Nevisense at the 2024 Winter Clinical Dermatology Conference in Miami
February 22, 2024STOCKHOLM, SWEDEN, - February 19, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders participated at the 2024 Winter Clinical Dermatology Conference in Miami. The second annual Winter Clinical Miami conference is a 4-day CME course that educates dermatologists on innovative news within Medical, and Surgical Dermatology. This prestigious CME course attracts over 400 dermatologists from the US and is considered to be one of the leading educational events for dermatology professionals.
New study shows Nevisense evaluates skin barrier function with less sensitivity to lifestyle factors than TEWL
February 16, 2024STOCKHOLM, SWEDEN, - February 16, 2024 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of the first direct comparison between electrical impedance spectroscopy (EIS) using Nevisense and trans-epidermal water loss (TEWL). The study demonstrates Nevisense as a more robust technique to assess skin barrier function than the commonly accepted TEWL measurement technique.
- Load more news...
News
We follow
Our commitment
At SciBase we stay true to our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention at the first signs of skin diseases and to reduce healthcare costs.
Skin Barrier Assessment
For Atopic Dermatitis
Nevisense is a unique, AI-based platform for the non-invasive, assessment of the skin barrier function. The measurements provide clinicians with objective and actionable data at point-of-care. Nevisense provides healthcare professionals with the ability to monitor therapeutic improvements and disease progression, while detect non-visual and subclinical inflammation.